These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26030144)

  • 21. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.
    Sorigue M; Mercadal S; Alonso S; Fernández-Álvarez R; García O; Moreno M; Pomares H; Alcoceba M; González-García E; Motlló C; González-Barca E; Martin A; Sureda A; Caballero D; Ribera JM; Sancho JM
    Hematol Oncol; 2017 Dec; 35(4):520-527. PubMed ID: 28156010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
    Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
    J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.
    Federico M; Guglielmi C; Luminari S; Mammi C; Marcheselli L; Gianelli U; Maiorana A; Merli F; Bellei M; Pozzi S; Stelitano C; Lazzaro A; Gobbi PG; Baldini L; Bergantini S; Fregoni V; Brugiatelli M
    Haematologica; 2007 Nov; 92(11):1482-8. PubMed ID: 18024396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of skeletal muscle abnormalities on tolerance to adjuvant chemotherapy and radiation and outcome in patients with endometrial cancer.
    Ganju RG; TenNapel M; Spoozak L; Chen AM; Hoover A
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):104-112. PubMed ID: 31397078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.
    Nabhan C; Byrtek M; Rai A; Dawson K; Zhou X; Link BK; Friedberg JW; Zelenetz AD; Maurer MJ; Cerhan JR; Flowers CR
    Br J Haematol; 2015 Jul; 170(1):85-95. PubMed ID: 25851937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
    Richendollar BG; Pohlman B; Elson P; Hsi ED
    Hum Pathol; 2011 Apr; 42(4):552-7. PubMed ID: 21237493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.
    Meignan M; Cottereau AS; Versari A; Chartier L; Dupuis J; Boussetta S; Grassi I; Casasnovas RO; Haioun C; Tilly H; Tarantino V; Dubreuil J; Federico M; Salles G; Luminari S; Trotman J
    J Clin Oncol; 2016 Oct; 34(30):3618-3626. PubMed ID: 27551111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical characteristics and survival analysis of
    Ying ZT; Feng HY; Mi L; Song YQ; Wang XP; Zheng W; Lin NJ; Tu MF; Xie Y; Ping LY; Zhang C; Liu WP; Deng LJ; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):745-750. PubMed ID: 30369186
    [No Abstract]   [Full Text] [Related]  

  • 30. Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?
    Etto LY; Silva VC; Inaoka RJ; Costa RP; Alves AC; Colleoni GW
    Leuk Lymphoma; 2007 Mar; 48(3):526-30. PubMed ID: 17454593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
    Marcus R; Imrie K; Solal-Celigny P; Catalano JV; Dmoszynska A; Raposo JC; Offner FC; Gomez-Codina J; Belch A; Cunningham D; Wassner-Fritsch E; Stein G
    J Clin Oncol; 2008 Oct; 26(28):4579-86. PubMed ID: 18662969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma.
    Li R; Wang T; Lyv R; Wang Y; Yu Y; Yan Y; Sun Q; Xiong W; Liu W; Sui W; Huang W; Wang H; Li C; Wang J; Zou D; An G; Wang J; Qiu L; Yi S
    Blood Sci; 2023 Apr; 5(2):118-124. PubMed ID: 37228779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follicular lymphoma: an Institutional Analysis.
    Gogia A; Raina V; Kumar L; Sharma A; Sharma MCh; Mallick SR
    Asian Pac J Cancer Prev; 2017 Mar; 18(3):681-685. PubMed ID: 28440975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.
    Rier HN; Jager A; Sleijfer S; van Rosmalen J; Kock MCJM; Levin MD
    Breast; 2017 Feb; 31():9-15. PubMed ID: 27810702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
    Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI;
    J Clin Oncol; 2006 Sep; 24(25):4143-9. PubMed ID: 16896003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma.
    Xue LG; Shen HR; Gao R; Du KX; Xing TY; Wang WT; Wang L; Li JY; Liang JH; Xu W
    Ann Hematol; 2023 Apr; 102(4):851-862. PubMed ID: 36735075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma.
    Pham RN; Gooley TA; Keeney GE; Press OW; Pagel JM; Greisman HA; Bensinger WI; Holmberg LA; Petersdorf SH; Maloney DG; Gopal AK
    Bone Marrow Transplant; 2007 Dec; 40(11):1039-44. PubMed ID: 17922043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience.
    Helbig G; Krawczyk-Kulis M; Kopinska A; Liwoch R; Kyrcz-Krzemien S
    Med Oncol; 2014 Dec; 31(12):310. PubMed ID: 25373321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study.
    Oh SY; Kwon HC; Kim WS; Park YH; Kim K; Kim HJ; Kwon JM; Lee J; Ko YH; Ahn YC; Oh SJ; Lee SI; Bang SM; Kim JH; Park J; Ryoo BY; Lee SS; Kim HY; Park K; Kim HJ
    Cancer Lett; 2007 Dec; 258(1):90-7. PubMed ID: 17936499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.